Skip to content

Clinical Application Research of Serum Amyloid A1 as a Biomarker for Sepsis-Associated Acute Respiratory Distress Syndrome

Clinical Application Research of Serum Amyloid A1 as a Biomarker for Sepsis-Associated Acute Respiratory Distress Syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118255
Enrollment
Unknown
Registered
2026-02-03
Start date
2026-02-15
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-associated acute lung injury,Sepsis-associated acute respiratory distress syndrome

Interventions

Case Group:None
control group:None

Sponsors

Chongqing Emergency Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age>=18; 2.Patients must be diagnosed with sepsis according to the Sepsis-3 guidelines and concurrently diagnosed with ARDS based on the ESICM guidelines. 3.Patients must have complete medical records and laboratory test data from admission to discharge. 4.The patients and their family members consent and are able to comply with the follow-up and data collection as required by the study.

Exclusion criteria

Exclusion criteria: 1.Patients who died within 24 hours of hospital admission. 2.Age<18; 3.Patients for whom detailed admission and discharge records, as well as other treatment data relevant to this study, cannot be obtained. 4.Patients with immunodeficiency diseases (such as HIV infection, immunosuppressive therapy recipients, solid organ transplant recipients, etc.) or patients receiving long-term immunosuppressive therapy (including corticosteroids, immunosuppressants, etc.) .. 5.Exclude patients who developed systemic inflammatory response syndrome (SIRS) due to non-infectious causes (such as pancreatitis or severe burns). 6.Patients with known underlying or recent medical conditions that could affect SAA1 levels (such as acute coronary syndrome or connective tissue disease). 7.Patients with severe liver disease (such as decompensated cirrhosis and acute liver failure). 8.Patients who are pregnant.

Design outcomes

Primary

MeasureTime frame
SAA1;

Secondary

MeasureTime frame
Liver Function Tests;Complete Blood Count;Arterial Blood Gas Analysis;Renal Function Tests;Coagulation Profile;

Countries

China

Contacts

Public ContactTao Shasha

Chongqing Emergency Medical Center

taoqishu619@126.com+86 23 6369 2483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026